Disney Illusion Island Now Available on Nintendo Switch™
28.7.2023 15:00:00 EEST | Business Wire | Press release
Today, Disney Games, in collaboration with developer Dlala Studios, launch Disney Illusion Island globally, a local cooperative 2D platform adventure video game for up to four players, exclusively for Nintendo Switch™.
Experience a brand-new adventure as players join Mickey Mouse, Minnie Mouse, Donald Duck and Goofy on a whimsical journey through the island of Monoth. Explore this beautiful yet mysterious world to recover the three magical Tomes – powerful books used to protect the island. Disney Illusion Island gives players the chance to be a part of an authentic Mickey & Friends adventure with an original story, stunning hand-drawn animation, and an original fully orchestrated score by Ivor Novello and BAFTA-nominated composer Dave Housden.
Watch the Disney Illusion Island Launch Trailer Here.
“Disney Illusion Island marks Mickey Mouse’s return to video games and we’re honored to bring this one-of-a-kind adventure to the Nintendo Switch,” said Luigi Priore, VP, Disney, Pixar and 20th Century Games. “We’re excited to see gamers jump in and explore the wonderfully hand-crafted world of Monoth with their friends and family.”
Featuring the authentic voice actors of Mickey, Minnie, Donald, and Goofy, Disney Illusion Island brings everyone together. Whether playing solo or teaming with up to three friends in local co-op, players will perform high flying platforming feats, uncover secrets, and take on epic boss encounters. There is always something new to discover in the expansive world of Monoth as players uncover the mystery of the stolen Tomes.
“Disney Illusion Island has been an absolute career high for myself and the studio,” said Aj Grand-Scrutton, Creative Director/CEO, Dlala Studios. “We have absolutely loved bringing Mickey, Minnie, Donald and Goofy back in a brand-new 2D platforming adventure and we can’t wait for players to join us in the world of Monoth!”
Disney Illusion Island is now available for $39.99, exclusively for Nintendo Switch on the Nintendo eShop and at retail, beginning today.
For more information about Disney Illusion Island: www.disneyillusionisland.com
For more updates on Disney Illusion Island, please follow us on social below:
About Disney Consumer Products, Games, and Publishing
Consumer Products, Games and Publishing (CPGP) is the division of Disney Parks, Experiences, and Products (DPEP) that brings beloved brands and franchises into the daily lives of families and fans through products – from toys to t-shirts, apps, books, console games and more – and experiences that can be found around the world, including on the shopDisney e-commerce platform and at Disney Parks, as well as local and international retailers. The business is home to world-class teams of product, licensing and retail experts, artists and storytellers, and technologists who inspire imaginations around the world.
About Dlala Studios
Dlala Studios are the creators of Disney Illusion Island and Battletoads (2020). They have also provided work for multiple award-winning titles, such as Sea of Thieves. The Essex-based studio has earned a reputation as an industry leader in 2D animation and for their unique, humorous narrative. The studio celebrated their 10th anniversary in 2022, growing to nearly 40 full-time employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230728085491/en/
Contact information
MEDIA CONTACTS
Dylan Quintero
Communications Manager
DYLAN.QUINTERO@DISNEY.COM
Melissa Lee
Senior Specialist, Communications
MELISSA.Y.LEE@DISNEY.COM
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom